On January 30, 2013, Mirna Therapeutics appointed Dr. Clay Siegall as an outside director to the company’s board of directors. Dr. Clay, Ph.D., is the co-founder, President and the current Chairman and Chief Executive Officer of the Board of Directors of Seattle Genetics. He was chosen as an outside director of Mirna Therapeutics due to his great experience in the production of pharmaceutical products geared in the fight against cancer. Mirna Therapeutics is a biotechnology company that specialized in the development of micoRNA therapeutics as well as its commercialization.
Dr. Clay Siegall graduated with a Ph.D. in Genetics from the George Washington University. He also holds a Bachelor of Science in Zoology degree from the University of Maryland. Prior to becoming the CEO of Seattle Genetics Dr. Siegall worked for the Bristol-Myers Squibb Pharmaceuticals Research Institute from 1991 to 1997. He had also worked at the National Institutes of Health and Cancer Institute from 1988 to 1991.
Seattle Genetics is a renowned biotechnology company that focuses on the development and commercialization of innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. Dr. Clay B. Siegall co-founded the Washington-based company in 1998. Under his leadership as the Chairman of the Board and CEO, Seattle Genetics has built a range of antibody-based therapies that aim to address the unmet needs of cancer patients. ADCETRIC is Seattle Genetics’ first commercial product which was approved in August 2011. ADCETRIS operates commercially in two indications in more than 50 countries including the United States, Canada, Japan and the EU. Throughout the years, the company has manufactured a wide pipeline of different product candidates. Seattle Genetics has also joined various strategic licenses for its ADC technology, including with companies such as Genentech, AbbVie, GSK and Pfizer under the leadership of Dr. Clay.
Seattle Genetics, whose initial public offering was in 2001, has engaged in capital-raising activities that have seen it secure more than $675 million under the leadership of Dr. Clay. He views MicroRNA-based therapeutics as an exciting area of cancer treatment and research. Mirna is indeed well positioned with an amazing pipeline of product candidates.